🇺🇸 FDA
Pipeline program

CINRYZE with rHuPH20

0624-204

Phase 2 mab completed

Quick answer

CINRYZE with rHuPH20 for Hereditary Angioedema is a Phase 2 program (mab) at HALOZYME THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
HALOZYME THERAPEUTICS, INC.
Indication
Hereditary Angioedema
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials